Table 3.

Novel biomarkers as prognostic indicators postbiopsy.

Sample	Assessment	Type	Indication
Tissue	Decipher	mRNA expression of 22 genes[56]	Indicated for men with adverse pathology post RP[56] Guide management for surveillance vs. radiation post-RP[56] Assess risk of metastases and PCa mortality after RP[21,56]
	Oncotype DX	mRNA expression of 17 genes[42]	Indicated for men with very low-, low-, and low- to intermediate-risk pathology[21,56] Assess tumor aggressiveness[21,42] Risk stratification, treatment decisions[56]
	Prolaris	mRNA expression of 31 genes[56]	Indicated for men with very low- and low-risk pathology[56] Assess tumor aggressiveness and recurrence[21,42,56] Guide management for surgery vs. radiation vs. active surveillance[56]
	ProMark Test	8 proteins[56]	Predicts tumor aggressiveness in men with Gleason score of 3 + 3 and 3 + 4[21,42]

mRNA = messenger ribonucleic acid; PCa = prostate cancer; RP = radical prostatectomy.